Raquel Aguiar-Ibáñez

ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 7

Top Venues

Journal of medical economics

Clinical drug investigation

Future oncology (London, England)

MSD BV

This page only lists publications with an associated author ORCID identifier.

Affiliation History

MSD BV Nov 29 2017

Netherlands

Principal Scientist :: Center for Observational and Real World Evidence (CORE)

Publications

Grant McCarthy, Kate Young, Matthew Madin-Warburton, Tyler Mantaian, Elizabeth Brook, Kaylie Metcalfe, Jan Mikelson, Ruifeng Xu, Carl Seyla-Hammer, Raquel Aguiar-Ibáñez, Mayur Amonkar
Cost-effectiveness of pembrolizumab for previously treated MSI-H/dMMR solid tumours in the UK. Journal of medical economics 27 (1) (2024)
Grant McCarthy, Kate Young, Matthew Madin-Warburton, Tyler Mantaian, Elizabeth Brook, Kaylie Metcalfe, Jan Mikelson, Ruifeng Xu, Carl Seyla-Hammer, Raquel Aguiar-Ibáñez, Mayur Amonkar
Cost-effectiveness of pembrolizumab for previously treated MSI-H/dMMR solid tumours in the UK. Journal of medical economics 27 (1) (2024)
Grant McCarthy, Kate Young, Matthew Madin-Warburton, Tyler Mantaian, Elizabeth Brook, Kaylie Metcalfe, Jan Mikelson, Ruifeng Xu, Carl Seyla-Hammer, Raquel Aguiar-Ibáñez, Mayur Amonkar
Cost-effectiveness of pembrolizumab for previously treated MSI-H/dMMR solid tumours in the UK. Journal of medical economics (2024)
Miranda Cooper, Sarah Smith, Troy Williams, Raquel Aguiar-Ibáñez
How accurate are the longer-term projections of overall survival for cancer immunotherapy for standard versus more flexible parametric extrapolation methods? Journal of medical economics 25 (1) (2022)
Raquel Aguiar-Ibáñez, Chloë Hardern, Frank van Hees, Dawn Lee, Anubhav Patel, Nitika Chhabra, Gargi Baluni, Mayur M Amonkar, Yizhen Lai, Ruifeng Xu, Rachid Massaad, David Fogelman
Cost-effectiveness of pembrolizumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer in the United States. Journal of medical economics 25 (1) (2022)
He Jin, Mayur M Amonkar, Raquel Aguiar-Ibáñez, Manasi Thosar, Monica Chase, Sam Keeping
Systematic literature review and network meta-analysis of pembrolizumab versus other interventions for previously untreated, unresectable or metastatic, MSI-high or MMR-deficient CRC. Future oncology (London, England) 18 (17) (2022)
Arielle G Bensimon, Zheng-Yi Zhou, Madeline Jenkins, Yan Song, Wei Gao, James Signorovitch, Clemens Krepler, Emilie Scherrer, Jingshu Wang, Raquel Aguiar-Ibáñez
An Economic Evaluation of Pembrolizumab Versus Other Adjuvant Treatment Strategies for Resected High-Risk Stage III Melanoma in the USA. Clinical drug investigation 40 (7) (2020)

Raquel Aguiar-Ibáñez.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Raquel Aguiar-Ibáñez